181 related articles for article (PubMed ID: 20922785)
1. A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Fury MG; Haque S; Stambuk H; Shen R; Carlson D; Pfister D
Cancer; 2011 Feb; 117(4):795-801. PubMed ID: 20922785
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Hensley ML; Larkin J; Fury M; Gerst S; Tai DF; Sabbatini P; Konner J; Orlando M; Goss TL; Aghajanian CA
Clin Cancer Res; 2008 Oct; 14(19):6310-6. PubMed ID: 18829514
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Villaflor VM; Haraf D; Salama JK; Kocherginsky M; Langerman A; Gomez-Abuin G; Beniwal P; Blair EA; Stenson KM; Portugal L; Seiwert T; Williams RD; Dekker AJ; Witt ME; Vokes EE; Cohen EEW
Ann Oncol; 2011 Nov; 22(11):2501-2507. PubMed ID: 21385883
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
von der Maase H; Lehmann J; Gravis G; Joensuu H; Geertsen PF; Gough J; Chen G; Kania M
Ann Oncol; 2006 Oct; 17(10):1533-8. PubMed ID: 16873433
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
[TBL] [Abstract][Full Text] [Related]
7. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
Spigel DR; Hainsworth JD; Barton JH; Patton JF; Zubkus JD; Simons L; Griner P; Burris HA; Greco FA
J Thorac Oncol; 2010 Jun; 5(6):841-5. PubMed ID: 20421819
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
Pippen J; Elias AD; Neubauer M; Stokoe C; Vaughn LG; Wang Y; Orlando M; Shonukan O; Muscato J; O'Shaughnessy JA; Gralow J
Clin Breast Cancer; 2010 Apr; 10(2):148-53. PubMed ID: 20299319
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Richey SL; Tamboli P; Ng CS; Lin E; Lim ZD; Araujo JC; Jonasch E; Sharma P; Pagliaro LC; Tannir NM
Am J Clin Oncol; 2013 Oct; 36(5):450-4. PubMed ID: 22706175
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer.
Stover DG; Lockhart AC; Berlin JD; Chan E; Sandler AB; Sosman JA; Middlebrook V; Nicol S; Rothenberg ML
Invest New Drugs; 2008 Aug; 26(4):339-45. PubMed ID: 18463792
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Dreicer R; Li H; Cooney MM; Wilding G; Roth BJ;
Cancer; 2008 Jun; 112(12):2671-5. PubMed ID: 18459175
[TBL] [Abstract][Full Text] [Related]
14. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Oettle H; Richards D; Ramanathan RK; van Laethem JL; Peeters M; Fuchs M; Zimmermann A; John W; Von Hoff D; Arning M; Kindler HL
Ann Oncol; 2005 Oct; 16(10):1639-45. PubMed ID: 16087696
[TBL] [Abstract][Full Text] [Related]
15. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
Kalykaki A; Vamvakas L; Agelaki S; Kalbakis K; Vardakis N; Sfakiotaki G; Ignatiadis M; Saridaki Z; Karampeazis A; Mavroudis D; Georgoulias V
Oncology; 2006; 71(3-4):197-203. PubMed ID: 17641541
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
Dent SF; Gertler S; Verma S; Segal R; Young V; Goel R; Keller O; Canil C; Iscoe N
Cancer Chemother Pharmacol; 2010 Feb; 65(3):557-61. PubMed ID: 19593565
[TBL] [Abstract][Full Text] [Related]
17. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Scagliotti GV; Park K; Patil S; Rolski J; Goksel T; Martins R; Gans SJ; Visseren-Grul C; Peterson P
Eur J Cancer; 2009 Sep; 45(13):2298-303. PubMed ID: 19473833
[TBL] [Abstract][Full Text] [Related]
18. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Comella P; Chiuri VE; De Cataldis G; Filippelli G; Maiorino L; Vessia G; Cioffi R; Mancarella S; Putzu C; Greco E; Palmeri L; Costanzo R; Avallone A; Franco L
Lung Cancer; 2010 Apr; 68(1):94-8. PubMed ID: 19545929
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
West HL; Wakelee HA; Perry MC; Belt RJ; Chen R; Obasaju C
Ann Oncol; 2009 May; 20(5):850-6. PubMed ID: 19150937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
